A Structural Shift in Consumer Behavior and Industry Strategy
May 2026
Executive Summary
Glucagon-like peptide-1 (GLP-1) receptor agonists — marketed under brand names such as Ozempic, Wegovy, Mounjaro, and Zepbound — have moved from niche diabetes treatments to mainstream weight-management medications with extraordinary speed. As of early 2026, an estimated one in eight U.S. adults has used or is currently using a GLP-1 drug, and adoption is accelerating as oral formulations reach the market, insurance coverage expands, and prices gradually decline. The pharmaceutical category itself has grown to roughly $76 billion in global annual sales in 2025, with forecasts suggesting it will reach $162 billion by 2031.
For the food and beverage (F&B) industry, this is not a niche wellness trend — it is a structural demand shock. GLP-1 receptor agonists represent the most consequential behavioral intervention in the history of the modern food and beverage industry. Unlike prior wellness trends — low-fat, low-carb, organic, plant-based — GLP-1 drugs do not depend on consumer willpower or ideology. They chemically alter the hunger and reward signals that the F&B industry has spent decades learning to stimulate. The result is a consumer who eats less, craves differently, and allocates food spending based on nutritional efficiency rather than hedonic appeal.
GLP-1 users consume an average of 21% fewer calories and spend approximately 31% less on groceries. JPMorgan estimates that by 2030, the cumulative effect of GLP-1 adoption could eliminate between $30 billion and $55 billion in annual F&B industry revenues. Categories built on impulse consumption — snack foods, confectionery, sugary beverages, alcohol — are already seeing measurable volume declines. At the same time, new opportunity is emerging around high-protein, high-fiber, nutrient-dense, and portion-controlled products, as companies race to meet the distinct dietary needs of a fast-growing and disproportionately high-spending consumer cohort.
I. The GLP-1 Adoption Curve
On the back of clinical trial results that showed patients on semaglutide (Ozempic and Wegoy) and tirzepatide (Mounjaro, Zepbound) lost 15-20% of body weight over roughly a year, and subsequent FDA approval in 2021, GLP-1 drug spending in the U.S. alone rose from $13.7 billion in 2018 to approximately $71.7 billion in 2023 — nearly a 500% increase — with Novo Nordisk’s and Eli Lilly’s combined platforms generating over $50 billion in global revenues by 2025. A Gallup survey tracking U.S. adults found that the share taking these medications for weight loss more than doubled over an 18-month window ending in late 2025, rising from 5.8% to 12.4% of respondents. A corresponding decline in the national obesity rate — from 39.9% three years prior to approximately 37% in 2025 — provides early confirmation that the drugs are producing real population-level effects.
The near-term trajectory points steeply higher. JPMorgan estimates that 30 million Americans will be on branded GLP-1 treatments by 2030, up from 10 million in 2026. That estimate does not account for compounded semaglutide, off-label usage, or the forthcoming wave of oral formulations. Novo Nordisk launched a Wegovy pill in January 2026, and Eli Lilly’s oral tirzepatide is in late-stage development. Oral delivery is expected to meaningfully accelerate uptake by removing the barrier of self-injection and reducing dosing complexity. Medicare’s 2025 decision to expand coverage for obesity — a population of roughly 67 million seniors — adds another significant growth driver. Circana projects that by 2030, households containing at least one GLP-1 user will account for 35% of all U.S. food and beverage units sold, up from 23% of households in late 2025. Needless to say, the food & beverage industry has taken notice.
II. How GLP-1 Drugs Change Eating Behavior
Understanding the F&B industry’s challenge and opportunity requires understanding exactly what GLP-1 drugs do to eating behavior. The medications work primarily by slowing gastric emptying and signaling satiety to the brain — users feel full faster, stay full longer, and experience dramatically reduced food cravings. The behavioral changes are profound and well-documented.
Research by Mattson — whose client roster includes PepsiCo, General Mills, McDonald’s, and Starbucks — found that GLP-1 users are consuming 66% less soda and alcohol, with 93% reporting that they eat smaller meals. More than 60% said they think about food less. KPMG’s consumer data found that GLP-1 users average 21% fewer calories consumed and spend roughly 31% less on grocery bills. A Cornell University and Numerator study published in late 2025 tracked actual grocery spending, finding that households with a GLP-1 user cut food spending by 5.3% on average — a figure that rose to 8% in higher-income households. Critically, among households that continued using the medication, reduced food spending persisted for at least a year, though the magnitude of the reduction moderated over time.
The nature of those spending reductions reveals a great deal about which F&B categories face structural risk. The Cornell study found that calorie-dense foods took the sharpest hits: spending on savory snacks declined approximately 10%, with similarly large decreases in sweets, baked goods, and cookies. Alcohol consumption declined as well, with a PwC study noting that roughly a third of heavy drinkers in its GLP-1 sample shifted into a lower drinking category. Bread and kitchen staples also declined. For an industry that has spent decades engineering products to stimulate cravings and drive repeat consumption, this erosion of food salience at the consumer level represents a genuinely novel challenge. The only categories showing meaningful increases were yogurt, fresh fruit, nutrition bars, and meat snacks.
III. Categories Under Pressure
Not all segments of the F&B industry face equal headwinds from GLP-1 adoption. The disruption is concentrated in specific, high-margin categories that have historically benefited from impulse purchase behavior and emotionally driven consumption — precisely the habits these medications suppress.
Snack Foods and Confectionery
Snacking was among the fastest-growing segments of the grocery market for most of the past decade. That growth story has now encountered a direct pharmaceutical countervailing force. EY-Parthenon estimates that GLP-1-related behavioral changes could erase up to $12 billion in snack sales over the next decade. A Bank of America Global Research note found that for limited-service restaurants like McDonald’s and Taco Bell, snacking accounts for 12% of spending — an exposure point that these chains can ill afford to see erode. The shift is not just about volume; it is about category loyalty. Users migrating away from chips, cookies, and candy and toward protein bars and meat snacks are often abandoning long-held brand relationships.
Sugary Beverages
The carbonated soft drink segment is navigating an already-challenging environment — health-conscious consumers and sugar taxes had already been reshaping demand — and GLP-1 adoption is adding further pressure. Coca-Cola’s then-CEO James Quincey acknowledged in an earnings call that GLP-1 users tend to drink less full-sugar soda, though he noted a corresponding shift toward diet sodas, hydration products, coffee, and — most notably — protein drinks. The company has been ramping up production of Fairlife, its protein-infused milk brand, in response. PepsiCo has launched its “Simply NKD” reformulation initiative and is rebranding Lay’s and Gatorade by removing artificial colors — a broader signal that the company sees a necessary repositioning toward clean-label, nutrient-conscious products.
Alcohol
Alcohol may be one of the most underappreciated pressure points in the GLP-1 landscape. Research from PwC highlights a structural concentration risk: the top 10% of U.S. alcohol drinkers account for nearly 60% of total alcohol sales. If a meaningful portion of heavy consumers begin using GLP-1 medications and shift into lower consumption categories — which the available survey data suggests is already occurring — the revenue impact could be disproportionate to the number of users affected. The category pressure is visible in both retail and foodservice channels.
Fast Food and Limited-Service Restaurants
Fast food operators are contending with a user base that is ordering smaller portions, making fewer impulse purchases, and gravitating away from calorie-dense value meals. The effect is not yet catastrophic, but the composition of that restaurant spending is shifting. Operators that can pivot toward protein-forward menus, smaller-format offerings, and macro-conscious choices are better positioned than those whose value propositions depend on supersized portions or high-calorie add-ons.
IV. The Opportunity Side: Winners in the GLP-1 Era
The same forces creating headwinds in certain categories are generating meaningful tailwinds elsewhere. GLP-1 users still spend — in fact, Circana’s research confirms that GLP-1 users as a cohort outspend non-users even as their overall food purchase volumes decline. They are directing that spending toward products with different nutritional profiles, and the companies that can capture that reallocated wallet are positioning themselves for durable growth.
High-Protein Foods
Protein has become the dominant nutritional callout in 2026 F&B marketing, and GLP-1 adoption is a primary driver. The clinical rationale is important: research published in the New England Journal of Medicine has found that up to 39% of weight lost on semaglutide can come from lean body mass rather than fat — a significant muscle-loss risk that dietitians recommend addressing through elevated protein intake. GLP-1 users are therefore motivated by both satiety (protein promotes fullness) and muscle preservation. Researchers recommend a minimum of 30 grams of protein per meal for users on these medications, a threshold that most conventional food products do not approach. This has opened a significant white space for reformulated and purpose-built products.
As the Bloomberg piece noted, frozen meals and TV dinners have become a particular battleground for this opportunity. Food companies are rushing to launch what they are calling “GLP-1-friendly” entrées — smaller-portioned, protein-dense, fiber-rich meals designed to deliver maximum nutrition in minimum volume. Nestlé launched Vital Pursuit, the first frozen meal line explicitly marketed to GLP-1 users, in May 2024, and has since expanded the range. Conagra’s Healthy Choice has added “GLP-1 Friendly” and “On Track” badging to 26 existing products, with additional SKUs in development. Newer entrants, including Counter (Macrofy Inc.), have built their entire brand proposition around delivering 30+ grams of protein per serving at under 400 calories, expanding to more than 1,650 Target locations by March 2026.
The catch, as consumer advocates and nutritionists have noted, is that “GLP-1 Friendly” is entirely unregulated as a label claim. There is no FDA-defined standard, leaving the designation open to marketing abuse and the credibility question is one the industry will need to reckon with, particularly as more sophisticated consumers and healthcare providers scrutinize ingredient panels.
Portion-Controlled and Nutrient-Dense Products
Beyond protein, GLP-1 users seek what nutritionists call “nutrient density” — the maximum delivery of vitamins, minerals, fiber, and quality macronutrients per calorie consumed. When someone is only going to eat 400 calories at a meal rather than 800, they want those 400 calories to count. This is driving reformulation across multiple categories: cereals, snack bars, ready meals, and even restaurant menus are being redesigned around nutrient efficiency rather than caloric abundance. UK supermarket chain Marks & Spencer has explicitly prioritized nutrient-per-calorie ratios in its GLP-1-friendly recipe development. Morrisons has partnered with sports nutrition brand Applied Nutrition to launch the UK’s first supermarket-exclusive GLP-1-friendly ready meal range, covering 53 products across approximately 400 stores.
Hydration and Functional Beverages
GLP-1 medications also suppress thirst signals, creating a physiological hydration risk for users who are already eating smaller portions. This creates genuine demand for hydration-focused beverages that do not carry significant caloric load. Coconut water, electrolyte drinks, enhanced waters, and low-sugar sports drinks are all benefiting. Simultaneously, protein shakes and high-protein lattes are posting strong growth as consumers look to meet elevated protein targets in convenient, drinkable formats. Starbucks has introduced protein cold foam drinks and protein breakfast pockets; Smoothie King has built a dedicated GLP-1 menu featuring high-protein, zero-added-sugar smoothies.
V. Industry Response: Reformulation, Repositioning, and the Capital Commitment
Major food and beverage conglomerates have moved from a wait-and-see posture to active strategic repositioning at notable speed. Nearly three dozen non-healthcare firms mentioned GLP-1 drugs or weight loss on earnings calls through early 2026, up from 14 in the prior year — a signal of how rapidly the topic has climbed executive agendas.
General Mills: CEO Jeffrey Harmening stated at the CAGNY investor conference that GLP-1 drugs will have “a lasting influence in the food and nutrition landscape,” nudging consumers toward smaller portions and more nutrient-dense foods. The company has launched Honey Nut Cheerios Protein, Ghost performance nutrition bars, and new granola lines, while its capital expenditure is projected to rise as much as 23% in 2026 to support reformulation and new product development.
PepsiCo: The company has launched its “Simply NKD” snack reformulation initiative and is rebranding Lay’s and Gatorade by removing artificial colors. It is also piloting mini-meal options through its Sabra and Siete brands — an acknowledgment that portion architecture itself must evolve. CEO Ramon Laguarta has signaled additional protein-forward product launches.
Coca-Cola: The company has ramped production of Fairlife protein-enriched milk to meet surging demand. Its incoming CEO, on his first analyst call, urged faster innovation across the portfolio, signaling urgency about the company’s positioning in the post-GLP-1 consumer landscape.
Conagra Brands: Conagra is investing in its Slim Jim meat stick franchise, nuts, and seeds — categories aligned with the protein-forward demand shift — and issued a report highlighting the outsized growth in protein-forward, portion-controlled, and nutrient-dense foods among Gen Z and millennial consumers. Its Healthy Choice labeling move, while criticized for lacking substantive reformulation, has at minimum demonstrated the commercial power of the GLP-1-friendly designation as a marketing signal.
Kraft Heinz: The company’s new chief executive halted a planned corporate split and instead committed $600 million in investments focused on reviving long-neglected protein staples, including its Oscar Mayer meat and cold cuts business — a bet on the durable appeal of protein-forward heritage brands.
Nestlé: Beyond the Vital Pursuit launch, Nestlé established an internal GLP-1 innovation task force that by 2025 had launched seven new SKUs across its Boost and Vital Proteins lines. The company is among the most explicitly committed to building a portfolio of products designed from the ground up for GLP-1 consumer nutrition needs.
The restaurant sector is pursuing parallel changes, with a notable pivot toward protein quantity transparency, smaller-format menu sections, and macro-conscious customization. Chipotle launched a High Protein Menu in late 2025 offering options ranging from 15 to 81 grams of protein. Shake Shack introduced its “Good Fit” menu. Olive Garden is testing a dedicated smaller-portion section for 2026. The Cheesecake Factory’s “Skinnylicious” menu section already caters to lighter appetite patterns at approximately 500 calories per dish
Conclusion
The rise of GLP-1 drugs represents a meaningful shift for the food and beverage industry, with long-term implications for consumer demand, category growth and product strategy. Hyde Park Capital’s Consumer industry group specializes in advising food and beverage companies as they navigate evolving market dynamics and pursue M&A, capital raising, and strategic advisory opportunities.
Key Sources and References
Bloomberg — “Frozen TV Dinners Get a High-Protein Makeover for the GLP-1 Era,” Kristina Peterson, May 6, 2026
CNBC — “GLP-1 drugs are changing how Americans eat. Food companies are racing to catch up,” March 21, 2026
Circana — “GLP-1 Medication Users to Represent 35% of U.S. Food and Beverage Sales by 2030,” November 2025
JPMorgan Global Research — “How Supply and Demand for Weight Loss Drugs is Playing Out in 2026,” February 2026
Cornell University / Numerator Study — “GLP-1 Users Cut Food Spending by 5.3%,” December 2025
Food Navigator USA — “The GLP-1 Effect: How 2026 Will Look for Food and Beverage,” December 2025
NPR — “What Does a GLP-1 Friendly Diet Look Like?” March 23, 2026
Retail Insider — “GLP-1 Drugs Trigger Multi-Billion Dollar Demand Shock in Food Sector,” May 2026
EY-Parthenon — GLP-1 Consumer Survey and Snack Sales Forecast Analysis, 2025–2026
Food Ingredients First — “New Year Menus Target GLP-1 Users Seeking High Protein and Low Carb Options,” January 2026
PwC — “What is the Future of GLP-1 Trends and Its Impact on Business Models,” 2025
KPMG — GLP-1 User Caloric Intake and Grocery Spending Research, 2025
Grand View Research / Market Intelligence — GLP-1 Weight Loss Drug Market Sizing, 2025–2030
Fox 5 DC / Vogue / Johns Hopkins Bloomberg School of Public Health — “Why Everything Is Suddenly Packed with Protein in the GLP-1 Era,” April 2026
By: Craig Lawson
Managing Director